Table 3.

ED₅₀ for the incidence of emesis, pica and nausea

	Ferret emesis	Dog emesis	Rat pica	Human emesis	Human nausea
Apomorphine
s.c.	0.056	0.013	n/a	0.016	0.011
i.v.	0.620	0.003	n/a	0.070	n/a
i.c.v.	n/c (<0.01)	0.001	n/a	n/a	n/a
i.m.	n/a	n/c (<0.034)	n/a	0.029	0.014
p.o.	n/a	2.439	n/a	n/a	n/a
CCK-8
i.v.	n/c (>0.05)	0.001	n/a	0.0004	n/c (<4.5×10−8)
Cisplatin
i.v.	2.447	0.316	n/a	n/c (<0.8)	n/c (<1.9)
i.p.	3.477	n/a	n/a	n/a	n/a
i.a.	n/a	n/c (>3.5)	n/a	n/a	n/a
Copper sulphate
p.o.	2.874	2.598	n/a	0.168	0.143
i.v.	n/a	2.221	n/a	n/a	n/a
Cyclophosphamide
i.v.	n/c (<50.0)	14.781	n/a	2.694	n/c (<2.7)
i.p.	100.000	n/a	n/a	n/a	n/a
Ipecacuanha
p.o.	0.314	n/c (<0.49)	n/a	0.041	0.091
LiCl
i.v.	n/c (<86.0)	n/a	n/a	n/a	n/a
p.o.	n/a	n/a	n/a	n/c (>3.74)	n/a
Morphine
s.c.	0.014	n/a	n/a	n/a	n/a
i.v.	n/c (<0.05)	0.036	n/a	n/c	n/c
i.c.v.	n/a	0.0003	n/a	n/a	n/a
i.m.	n/a	0.506	n/a	n/a	n/c
p.o.	n/a	3.614	n/a	n/a	n/a
i.t.	n/a	n/a	n/a	0.005	n/c
Nicotine
s.c.	3.368	n/a	n/a	n/a	n/a
i.v.	n/a	n/c (<0.081)	n/a	n/a	n/a
i.m.	n/a	3.972	n/a	n/a	n/a
p.o.	n/a	n/c (>13.4)	n/a	0.126	n/c (>0.046)
t.d.	n/a	2.235	n/a	1.169	0.0385
inhalation	n/a	n/a	n/a	n/c (>0.034)	n/c (>0.034)
Rolipram
i.v.	n/a	0.189	n/a	n/a	n/a
p.o.	0.842	0.062	0.479	n/a	0.030
s.c.	n/c	n/a	n/a	n/a	n/a
i.c.v.	n/c	n/a	n/a	n/a	n/a

ED₅₀ (dose at which 50% of the individuals developed emesis, pica or nausea) are expressed in mg·kg⁻¹, expect for i.c.v. administration which is expressed in mg. ED₅₀ were extrapolated following a sigmoidal curve fit (variable slope, normalized); values in parentheses are given as indications, when the data were too limited to fit a curve. n/c: not computed (the data available were not sufficient to enable ED₅₀ calculation). n/a: not available (there were no data for that species at that mode of administration).